Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board
June 15 2020 - 8:00AM
Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:
ZIOP), today announced the appointment of renowned oncology and
immunotherapy pioneer, Carl June, M.D., as Chairman of its newly
formed Scientific Advisory Board (SAB). Dr. June is recognized in
the oncology field for his groundbreaking work in the development
and commercialization of gene therapy and T-cell therapies. The SAB
will provide strategic counsel to guide the efficient development
of Ziopharm’s innovative technologies and pipeline of
immunotherapies to treat the many patients with solid tumors.
“We are pleased to welcome Dr. June as the
leader of our SAB,” said Laurence Cooper, M.D., Ph.D., Chief
Executive Officer of Ziopharm. “His unmatched experience and
immense knowledge of immuno-oncology and cell therapies is a key
addition for Ziopharm. We look forward to Carl’s guidance helping
to develop our T-cell receptor program in our fight against solid
tumors.”
Dr. June added, “Ziopharm has built a robust,
scientifically-validated T-cell therapy program based on the
Sleeping Beauty platform that offers the potential to transform the
state of cancer care. I am excited to lead Ziopharm’s SAB and look
forward to working with other experts, and the Company’s strong
internal team, to help advance Ziopharm’s portfolio of cell and
gene therapies toward commercialization.”
Dr. June has published more than 500 manuscripts
on immunotherapy. He currently serves as the Richard W. Vague
Professor in immunotherapy in the Department of Pathology and
Laboratory Medicine and as the Director of the Center for Cellular
Immunotherapies at the Perelman School of Medicine, as well as the
Director of the Parker Institute for Cancer Immunotherapy at the
University of Pennsylvania. He is the recipient of numerous awards
and honors, including his election into the National Academies of
Medicine and Science and the American Academy of Arts and Sciences.
In 2018, Dr. June was named one of Time Magazine's 100 Most
Influential People for his work in the oncology field. Dr. June
graduated from the U.S. Naval Academy and earned his medical degree
from the Baylor College of Medicine. He also completed training in
immunology and malaria at the World Health Organization and
completed his postdoctoral training in transplantation biology with
the late Nobel Prize winner Dr. E. Donnall Thomas at the Fred
Hutchinson Cancer Research Center.
About Ziopharm Oncology,
Inc. Ziopharm is developing non-viral and cytokine-driven
cell and gene therapies that weaponize the body’s immune system to
treat the millions of people globally diagnosed with a solid tumor
each year. With its multiplatform approach, Ziopharm is at the
forefront of immuno-oncology with a goal to treat any type of solid
tumor. Ziopharm’s pipeline is built for commercially scalable, cost
effective T-cell receptor T-cell therapies based on its
non-viral Sleeping Beauty gene transfer platform, a
precisely controlled IL-12 gene therapy, and rapidly
manufactured Sleeping Beauty-enabled CD19-specific CAR-T
program. The Company has clinical and strategic partnerships with
the National Cancer Institute, The University of Texas MD
Anderson Cancer Center and others. For more information,
please visit www.ziopharm.com
Forward-Looking Statements
DisclaimerThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as "may," "will," "could," "expects," "plans,"
"anticipates," and "believes." These statements include, but are
not limited to, statements regarding the Company's business,
strategic and commercialization plans. Although Ziopharm’s
management team believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Ziopharm, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, changes in our operating plans that may impact
our cash expenditures, the uncertainties inherent in research and
development, future clinical data and analysis, including whether
any of Ziopharm’s product candidates will advance further in the
preclinical research or clinical trial process, including receiving
clearance from the U.S. Food and Drug Administration or equivalent
foreign regulatory agencies to conduct clinical trials and whether
and when, if at all, they will receive final approval from the U.S.
FDA or equivalent foreign regulatory agencies and for which
indication; the strength and enforceability of Ziopharm’s
intellectual property rights; competition from other pharmaceutical
and biotechnology companies as well as risk factors discussed or
identified in the public filings with the Securities and Exchange
Commission made by Ziopharm, including those risks and
uncertainties listed in Ziopharm’s Quarterly Report on Form 10-Q
filed by Ziopharm with the Securities and Exchange Commission. We
are providing this information as of the date of this press
release, and Ziopharm does not undertake any obligation to update
or revise the information contained in this press release whether
as a result of new information, future events or any other
reason.
Investor Relations
Contacts:Ziopharm Oncology:Chris TaylorVP, Investor
Relations and Corporate CommunicationsT: 617.502.1881E:
ctaylor@ziopharm.com
LifeSci Advisors: Mike MoyerManaging DirectorT:
617.308.4306E : mmoyer@lifescicomms.com
Media Relations Contact:LifeSci
Communications:Patrick BurseyT: 646.876.4932E:
pbursey@lifescicomms.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Sep 2023 to Sep 2024